Current Literature

  1. Blok JL, van Hattem S, Jonkman MF, Horvath B. systemic therapy with immunosuppressive agents and retinoids in hidradentitis suppurativa: a systemic review. BrJDermatol 2013;168(2):243-52.
  2. Canoui-Poitrine F, LeThuaut A, Revuz JE, et al. identification of three hidradenitis suppurativ phenotypes: latent class analysis of a cross-sectional study. J Invest Dermatol 2013;1506-11.
  3. Danby FW. Commentary: unroofing for hidradenitis suppurativa, why and how. J Am Acad Dermatol 2010 Sep;63(3):481-3.
  4. Danby FW, Jemec GB, Marsch WC, vonLaffert M. Preliminary findings suggest hidradenitis suppurativa may be due to defective follicular support. Br J Dermatol 2013 May;168(5):1034-9.
  5. Danby FW. Turning acne on/off via mTORC1. Exp Dermatol 2013 Jul;22(7):505-6. This article is Open Access at
  6. DeSouza A, Solomon GE, Strober BE. SAPHO syndrome associated with hidradenitis suppurativa successfully treated with infliximab and methotrexate. Bull NYU Hosp Jt Dis 2011;69(2): 185-7.
  7. Finlay AY, Khan GK. Dermatology life quality index (DLQI): a simple practical measure for routine clinical use. Clinical and Exp Dermatol 194;19:210-6.
  8. Ingram JR, Piguet V. Phenotypic heterogeneity in hidradenitis suppurativa (acne inversa): classification is an essential step towards personal therapy. J Invest Dermatol 2013;133:1453-6.
  9. Jemec G, Ruvez J, Leyden J (eds). Hidradenitis Suppurativa. 1st Ed. Heidelberg, Germany. Springer, 2006.
  10. Kimball AB, Gu Y, Okun M. Treatment of moderate to severe hidradenitis suppurativa. Ann Int Med 2013;159:72-3.
  11. Kimball AB, Kerdel F, Adams D, et al. Adalimumab for the treatment of moderate to severe hidradenitis suppurativa: a parallel randomized trial. Ann Int Med 2012;158:846-55.
  12. Marzano AV, Trevisan V, Gattorno M, et al. Pyogenic arthritis, pyoderma gangrenosum, acne, and hidradenitis suppurativa (PAPASH): a new autoinflammatory syndrome associate with a novel mutation of the PSTPIPI gene. JAMA Dermatol 2013;149:762-4.
  13. Melnik BC, Plewig G. Impaired Notch-MKP-1 signalling in hidradenitis suppurativa: an approach to pathogenesis by evidence from transitional biology. Exp Dermatol. 2-13;22:172-7.
  14. Melnik BC, Zouboulis CC. Potential role of FoxO1 and mTORC1 in the pathogenesis of Western diet-induced acne. Exp Dermatol 2013 May;22(5):311-5. This article is Open Access at
  15. Rambhatia PV, Lim HW, Hamzavi I. A systematic review of treatments for hidradenitis suppurativa. Arch Dermatol 2012;148(4):439-46.
  16. Sartorius K, Lapins T, Emtestam L, Jemec G. Suggestions for uniform outcome variables when reporting treatment effects in hidradenitis suppurativa. Br J Dermatol. 2003;149(1):211-3.
  17. Wolkenstein P, Loundou A, Barrau K, Auquier P, Ruvez J. Quality of life impairment in hidradenitis suppurativa: a study of 61 cases. J Am Acad Dermatol. 2007;56(4):621-3.
  18. Scheinfeld N. Hidradenitis suppurativa: A practical review of possible medical treatments based on over 350 hidradenitis patients. Online Journal. 2013.